Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
CAMBRIDGE, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics (Nasdaq: NTGN) has been named one of the top places to work in Massachusetts by The Boston Globe, an honor awarded based on employee feedback.
The Top Places to Work awards recognize the most admired workplaces in the state, as voted on by the employees of those companies. The annual survey, now in its 11th year, measures employee opinions about their company’s direction, management, culture, pay and benefits and engagement with employees, among other factors.
Neon was ranked first among the small biotech companies surveyed and sixth overall among Massachusetts companies with fewer than 100 employees.
“We’re especially proud of this honor because the recognition is based on accolades coming straight from our own team,” said Hugh O’Dowd, President and Chief Executive Officer of Neon. “I consider it my most important job as CEO to nurture a culture that lets every Neon employee do their best work, while building a sense of common mission. It’s wonderful to have our approach affirmed through this award.”
The Boston Globe’s rankings are based on confidential surveys collected by Energage (formerly WorkplaceDynamics), an independent company specializing in employee engagement and retention. Surveys were collected this year from more than 82,000 individuals at 318 organizations across the state. The winners share several common traits, including giving employees a voice in the workplace, cultivating a culture that makes time for fun and offering strong benefit packages.
Details about the winning companies were published online Thursday night and will appear in print in The Boston Globe Magazine on Nov. 18.
About Neon TherapeuticsNeon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer. For more information, please visit www.neontherapeutics.com.
About Boston Globe Media Partners LLCBoston Globe Media Partners, LLC provides news and information, entertainment, opinion and analysis through its multimedia properties. BGMP includes The Boston Globe, BostonGlobe.com, Boston.com, STAT and Globe Direct.
Media Contact: Stephanie Simon, Ten Bridge Communications email@example.com 617-581-9333
Investor Contact: Will O’Connor, Stern Investor Relations firstname.lastname@example.org 212-362-1200